Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Has results × Advanced Cancer × Everolimus × Clear all

Sponsor

Conditions

Breast Neoplasms 34 Carcinoma, Renal Cell 29 Neoplasms 17 Kidney Neoplasms 15 Neuroendocrine Tumors 13 Neoplasm Metastasis 12 Tuberous Sclerosis 8 Prostatic Neoplasms 8 Carcinoma 8 Lymphoma, Mantle-Cell 7 Hodgkin Disease 7 Waldenstrom Macroglobulinemia 6 Recurrence 6 Lymphoma, Large B-Cell, Diffuse 6 Head and Neck Neoplasms 6 Glioma 6 Triple Negative Breast Neoplasms 5 Ovarian Neoplasms 5 Lymphoma 5 Glioblastoma 5 Colorectal Neoplasms 5 Carcinoma, Neuroendocrine 5 Brain Neoplasms 5 Astrocytoma 5 Sezary Syndrome 4 Sarcoma 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Pancreatic Neoplasms 4 Mycosis Fungoides 4 Melanoma 4

Interventions

Nivolumab 7 linrodostat 3 Ipilimumab 3 relatlimab 2 Pemetrexed 2 tislelizumab 1 regorafenib 1 ralimetinib 1 p38 Mitogen-Activated Protein Kinases 1 figitumumab 1 efatutazone 1 abemaciclib 1 Vorinostat 1 Tamoxifen 1 Sunitinib 1 Ranitidine 1 Midazolam 1 LY2603618 1 LY2584702 1 Gemcitabine 1 Fulvestrant 1 Dasatinib 1 Crizotinib 1 Cetuximab 1 Carboplatin 1 BMS-813160 1 3-(9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro(1,4)diazepino(6,7,1-hi)indol-7-yl)-4-imidazo(1,2-a)pyridin-3-yl-1H-pyrrole-2,5-dione 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡